Jubilant Pharmova Ltd
NSE: JUBLPHARMA BSE: 530019
₹1002.95
(-1.11%)
Sun, 24 May 2026, 11:54 pm
Market Cap161.38B
PE Ratio36.81
Dividend0.49
Health Technology
Pharmaceuticals: Major
24.5KJubilant Pharmova Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (11.3x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (15.5x coverage).
- Dividends per share have been stable in the past 10 years.
- Jubilant Life Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Jubilant Life Sciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Jubilant Life Sciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Jubilant Life Sciences's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- Cash flow for Jubilant Life Sciences is expected to increase but not above the 50% threshold in 2 years time.
- Jubilant Life Sciences's earnings are expected to grow by 13.9% yearly, however this is not considered high growth (20% yearly).
- Jubilant Life Sciences's earnings growth is positive but not above the India market average.
- Jubilant Life Sciences's net income is expected to increase but not above the 50% threshold in 2 years time.
- Jubilant Life Sciences is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- A decline in Jubilant Life Sciences's performance (ROE) is expected over the next 3 years.
- Jubilant Life Sciences's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Jubilant Life Sciences's revenue is expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
- Jubilant Life Sciences's revenue growth is positive but not above the India market average.
health
- Jubilant Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Jubilant Life Sciences is profitable, therefore cash runway is not a concern.
- Jubilant Life Sciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (35.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.1x debt.
- Jubilant Life Sciences's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (195.2% vs 78.3% today).
- Interest payments on debt are well covered by earnings (EBIT is 5.2x coverage).
- Jubilant Life Sciences's level of debt (78.3%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Jubilant Life Sciences board of directors is about average.
- Hari's compensation has been consistent with company performance over the past year, both up more than 20%.
- More shares have been bought than sold by Jubilant Life Sciences individual insiders in the past 3 months.
- The average tenure for the Jubilant Life Sciences management team is over 5 years, this suggests they are a seasoned and experienced team.
- Hari's remuneration is higher than average for companies of similar size in India.
misc
- Jubilant Life Sciences has significant price volatility in the past 3 months.
past
- Jubilant Life Sciences's 1-year earnings growth exceeds its 5-year average (56.4% vs 22.2%)
- Jubilant Life Sciences has delivered over 20% year on year earnings growth in the past 5 years.
- Jubilant Life Sciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Jubilant Life Sciences has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Jubilant Life Sciences's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (56.4% vs 22.7%).
- Jubilant Life Sciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Jubilant Life Sciences is good value based on expected growth next year.
- Jubilant Life Sciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
- JUBILANT outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- JUBILANT outperformed the Market in India which returned -14.5% over the past year.
- NSEI:JUBILANT is up 39.1% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:JUBILANT is up 39.1% outperforming the market in India which returned 8% over the past month.
- Jubilant Life Sciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Jubilant Life Sciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Jubilant Life Sciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Jubilant Life Sciences is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800